Similar Articles
381 Peroxisome proliferator-activated receptor gamma as a therapeutic target for hepatocellular carcinoma: Experimental and clinical scenarios
382 Combination approaches in hepatocellular carcinoma: How systemic treatment can benefit candidates to locoregional modalities
383 Non-alcoholic fatty liver disease-related hepatocellular carcinoma: Is there a role for immunotherapy?
384 Gut microbiota contribution to hepatocellular carcinoma manifestation in non-alcoholic steatohepatitis
385 Hepatocellular carcinoma and microbiota: Implications for clinical management and treatment
386 Impact of comorbid renal dysfunction in patients with hepatocellular carcinoma on long-term outcomes after curative resection
387 miR-3682-3p directly targets FOXO3 and stimulates tumor stemness in hepatocellular carcinoma via a positive feedback loop involving FOXO3/PI3K/AKT/c-Myc
388 Clinical values of Barcelona Clinic Liver Cancer subgroup and up-to-7 criteria in intermediate stage hepatocellular carcinoma with transcatheter arterial chemoembolization
389 Application of intravoxel incoherent motion diffusion-weighted imaging in hepatocellular carcinoma
390 Regulatory T cells and their associated factors in hepatocellular carcinoma development and therapy
© 2004-2025 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA